 - Allogeneic stem cell reinfusion: Patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0. Patients then receive filgrastim G-CSF subcutaneously daily beginning on day 7 and continuing until blood counts recover. 